SynthesisDiabetes & metabolic syndrome
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials".
Synthesis in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials.Scientific reports · 2021Pooled it
- Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.Clinical and translational science · 2021Pooled it
- Current evidence for COVID-19 therapies: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2021Pooled it
- Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial.Journal of medical virology · 2022Trial
- Risk Factors for QT Prolongation in Patients with Chronic Hydroxychloroquine Use.Acta Cardiologica Sinica · 2022Article
- COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?Pharmacological research · 2022Review
- Review
- Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.Bioorganic & medicinal chemistry · 2022Article
- Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection.Medical journal, Armed Forces India · 2021Article
- Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver.Journal of clinical and translational hepatology · 2021Review
- Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion.Experimental & molecular medicine · 2021Article
- Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review).International journal of molecular medicine · 2021Review
- Precision therapeutic targets for COVID-19.Virology journal · 2021Review
- Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.Journal of pharmaceutical and biomedical analysis · 2021Article
- Easing COVID-19 lockdown measures while protecting the older restricts the deaths to the level of the full lockdown.Scientific reports · 2021Article
- Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective.3 Biotech · 2021Review
- Keeping Meta-Analyses Hygienic During the COVID-19 Pandemic.Frontiers in public health · 2021Article
- It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?Archives of medical science : AMS · 2021Article
- Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study.Journal of immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCoronavirus pandemic is currently a global public health emergency with no definitive treatment guidelines. We conducted a systematic review and meta-analysis of the literature evaluating the efficacy of hydroxychloroquine and its related formulations in COVID-19 patients.
methodsA systematic search of PubMed, Scopus, MedRxiv data and Cochrane Central Register of Clinical Trials for published articles that reported the outcomes of COVID-19 patients treated with hydroxychloroquine or its compounds was done. We identified 1071 published studies and 7 studies were included in the analysis.
resultsThe study population consisted of a total of 4984 patients, of which 1721 (34.5%) received hydroxychloroquine or its congeners (HCQ group) while 3091 (62.01%) received standard of care or had included antiviral medication (control group). The pooled estimate of successful treatment in the hydroxychloroquine group and the control group was 77.45% and 77.87% respectively, which indicated similar clinical outcomes in patients treated with hydroxychloroquine compared to the control group. The odds ratio of a favourable outcome with hydroxychloroquine was 1.11 (95 CI 0.72 to 1.69) (p = 0.20). The pooled risk difference of favourable outcome with hydroxychloroquine versus control group was 0.00 (95 CI -0.03 to 0.03) which was statistically not significant (p = 0.10).
conclusionsThe present evidence shows no benefit of hydroxychloroquine in patients affected by mild to moderate COVID-19 disease. However, now several trials on HCQ are ongoing and hopefully more data will be available soon. Hence, the management of COVID-19 is set to change for better in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.